XML 39 R29.htm IDEA: XBRL DOCUMENT v3.7.0.1
Acquisitions (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Jul. 05, 2016
Sep. 30, 2015
Apr. 30, 2017
Apr. 30, 2016
Jun. 30, 2017
Mar. 31, 2017
Jun. 30, 2017
Jun. 30, 2016
Dec. 31, 2016
Acquisitions                  
Common stock, par value (in dollars per share)         $ 0.01   $ 0.01   $ 0.01
Contingent consideration payable         $ 265,350   $ 265,350   $ 269,722
Contingent consideration payable, current portion         46,188   46,188   $ 56,101
Changes in fair value of contingent consideration payable             5,628 $ 13,338  
Scioderm                  
Acquisitions                  
Initial amount to Effective Time Holders   $ 223,900              
Initial amount cash payment excluding Series B Preferred   141,100              
Initial amount paid in shares of Common Stock   $ 82,800              
Priority review voucher transfer years   1 year              
Payment to be made if Priority Review Voucher is obtained and used   $ 100,000              
Contingent consideration payable   259,000     254,700   254,700    
Enrollment rate (as a percent)           100.00%      
Milestone payment     $ 10,000            
Contingent consideration payable, current portion         46,200   46,200    
Scioderm | Changes in fair value of contingent consideration payable                  
Acquisitions                  
Changes in fair value of contingent consideration payable         700        
Scioderm | Maximum                  
Acquisitions                  
Priority Review Voucher sale proceeds shared   $ 100,000              
Priority Review Voucher sale proceeds shared (as a percent)   50.00%              
Scioderm | Amicus | Common Stock                  
Acquisitions                  
Consideration paid in common stock   5,900,000              
MiaMed Inc                  
Acquisitions                  
Asset acquisition, total consideration, stock and cash $ 6,500                
Asset acquisition, cash consideration paid 1,800                
Asset acquisition, potential aggregate deal value 89,500                
Charges to research expense for stock issued in asset acquisition $ 6,500                
MiaMed Inc | Amicus | Common Stock                  
Acquisitions                  
Asset acquisition, consideration paid in common stock 825,603                
Common stock, par value (in dollars per share) $ 0.01                
Clinical, Regulatory and Commercial milestones | MiaMed Inc | Maximum                  
Acquisitions                  
Contingent consideration payable upon achievement of milestones $ 83,000                
Clinical and Regulatory Approval milestones | Scioderm                  
Acquisitions                  
Contingent consideration payable         228,100   228,100    
Clinical and Regulatory Approval milestones | Scioderm | Minimum                  
Acquisitions                  
Discount rate (as a percent)   0.40%              
Clinical and Regulatory Approval milestones | Scioderm | Maximum                  
Acquisitions                  
Upfront cash payments   $ 361,000   $ 361,000          
Discount rate (as a percent)   1.10%              
Clinical and Regulatory Approval milestones | MiaMed Inc | Maximum                  
Acquisitions                  
Contingent consideration payable upon achievement of milestones $ 83,000                
Revenue-based milestones | Scioderm                  
Acquisitions                  
Upfront equity payments   $ 257,000              
Contingent consideration payable         $ 26,600   26,600    
Revenue-based milestones | Scioderm | Minimum                  
Acquisitions                  
Discount rate (as a percent)   1.00%              
Revenue-based milestones | Scioderm | Maximum                  
Acquisitions                  
Upfront equity payments             $ 257,000    
Discount rate (as a percent)   2.20%              
Clinical milestone | Scioderm | Maximum                  
Acquisitions                  
Upfront cash payments       81,000          
Regulatory Approval milestone | Scioderm | Maximum                  
Acquisitions                  
Upfront cash payments       $ 280,000